How can a prediabetic woman manage weight at age 34?

Question

Hello doctor,

I am a 34-year-old woman with a BMI of 39 and prediabetes. Despite dieting and regular walking, I continue to gain weight, especially around my abdomen. My doctor has suggested GLP-1 injections such as Semaglutide, but I am concerned about long-term safety and cost.

How effective are these medications compared to bariatric surgery in preventing diabetes and heart disease?
If I choose surgery, which option, gastric sleeve or gastric bypass, provides better long-term results for someone my age?

Please help.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I have gone through your query and understand your concern.

Both options are highly effective, but they work in different ways. GLP-1 (glucagon-like peptide) medications reduce the progression from prediabetes (blood sugar levels are higher than usual but not yet diabetic) to type 2 diabetes (where the body either does not make enough insulin or does not use insulin properly) by approximately 70 to 90 percent, according to recent data.

They also reduce major cardiovascular events such as heart attack and stroke (poor blood flow to a part of the brain causes cell death) by about 20 percent in patients who already have heart disease. These benefits tend to reduce if the medication is stopped and weight is regained.

Bariatric surgery, including gastric bypass and sleeve gastrectomy, offers a diabetes remission rate of around 60 to 80 percent at five to 10 years. Long-term cardiovascular risk reduction, including heart attack and stroke, is about 30 to 40 percent. These benefits often persist even if some weight is regained because the surgery permanently alters gut hormones.

For diabetes prevention or remission and long-term heart protection, surgery remains superior, although GLP-1 medications come close and have the advantage of being noninvasive.

In your age group, gastric bypass generally provides slightly higher total weight loss, better diabetes remission rates, and stronger long-term metabolic effects compared to sleeve gastrectomy.

Regarding safety, long-term studies of GLP-1 medications extending beyond five years show serious side effects such as pancreatitis (pancreas inflammation) and gallbladder disease in fewer than 2 percent of patients. Concerns about thyroid tumors remain theoretical, as this has not been reported in humans so far.

Most patients tolerate these medications well when doses are adjusted appropriately. Cost remains a limiting factor unless subsidized.

Given your history of breast cancer, I strongly recommend opting for GLP-1 injections.

I hope I have answered your question.

Let me know if I can assist you further.

Thank you.